Below are the most recent publications written about "Drug Compounding" by people in Profiles.
-
Porat-Dahlerbruch G, Struppe J, Quinn CM, Gronenborn AM, Polenova T. 19F fast MAS (60-111?kHz) dipolar and scalar based correlation spectroscopy of organic molecules and pharmaceutical formulations. Solid State Nucl Magn Reson. 2022 12; 122:101831.
-
Rochani A, Nguyen V, Becker R, Kaushal G. Stability-indicating HPLC method to determine the stability of extemporaneously prepared vancomycin oral solution cups. Am J Health Syst Pharm. 2022 Jan 01; 79(1):e34-e40.
-
Kleinmann N, Matin SF, Pierorazio PM, Gore JL, Shabsigh A, Hu B, Chamie K, Godoy G, Hubosky S, Rivera M, O'Donnell M, Quek M, Raman JD, Knoedler JJ, Scherr D, Stern J, Weight C, Weizer A, Woods M, Kaimakliotis H, Smith AB, Linehan J, Coleman J, Humphreys MR, Pak R, Lifshitz D, Verni M, Adibi M, Amin MB, Seltzer E, Klein I, Konorty M, Strauss-Ayali D, Hakim G, Schoenberg M, Lerner SP. Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. Lancet Oncol. 2020 06; 21(6):776-785.
-
Bushra R, Rehman A, Ghayas S, Zafar F, Ali H, Shafiq Y, Khalid F, Khan MA, Hanif A, Mustapha O. Formulation design, characterization and optimization of cinitapride (1mg) immediate release tablets using direct compression technology. Pak J Pharm Sci. 2018 Nov; 31(6 (Supplementary):2725-2731.
-
Rehman A, Bushra R, Beg AE, Ali H, Zafar F, Ashfaq M, Alam S, Mustapha O, Shafique S. Effects of superdisintegrants in oral dissolving formulation of cinitapride tablets. Pak J Pharm Sci. 2018 Mar; 31(2(Suppl.)):643-650.
-
Penazzato M, Gnanashanmugam D, Rojo P, Lallemant M, Lewis LL, Rocchi F, Saint Raymond A, Ford N, Hazra R, Giaquinto C, Belew Y, Gibb DM, Abrams EJ. Optimizing Research to Speed Up Availability of Pediatric Antiretroviral Drugs and Formulations. Clin Infect Dis. 2017 Jun 01; 64(11):1597-1603.
-
Tyson SL, Bailey R, Roman JS, Zhan T, Hark LA, Haller JA. Clinical outcomes after injection of a compounded pharmaceutical for prophylaxis after cataract surgery: a large-scale review. Curr Opin Ophthalmol. 2017 Jan; 28(1):73-80.
-
Storey PP, Ho V, Yeh S, Reddy S, Fang-Yen NH, Pequignot E, Leiby BE, Fineman M, Garg S, Hubbard GB, Hsu J. INCIDENCE OF SUSTAINED OCULAR HYPERTENSION USING PREPACKAGED VERSUS FRESHLY PREPARED INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2015 Oct; 35(10):1992-2000.
-
Napper AD. A new chapter for ASSAY and drug development technologies. Assay Drug Dev Technol. 2015 Jan-Feb; 13(1):1.
-
Yannuzzi NA, Klufas MA, Quach L, Beatty LM, Kaminsky SM, Crystal RG, D'Amico DJ, Kiss S. Evaluation of compounded bevacizumab prepared for intravitreal injection. JAMA Ophthalmol. 2015 Jan; 133(1):32-9.